The global manufacturer of HYPURIN Porcine has stopped producing vial presentations, but the product will still be available in cartridge form, which requires a pen for administration. Aspen has been managing access to HYPURIN Porcine products through the Special Access Scheme (SAS) for years and is now transferring full management to HL Pharma Pty Ltd. HL Pharma will provide a streamlined service with a focus on personalised care. This change will take effect on 1 October 2025.




















